前沿生物(688221) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 129.47 million, an increase of 13.32% compared to RMB 114.25 million in the previous year[4] - The net loss attributable to the parent company was RMB 201.52 million, a reduction in loss of RMB 12.74 million from RMB 328.96 million in the previous year[6] - Total assets at the end of the reporting period were RMB 1.81 billion, a decrease of 15.33% from RMB 2.14 billion at the beginning of the period[4] - The equity attributable to the parent company decreased by 15.01% to RMB 1.14 billion from RMB 1.34 billion at the beginning of the period[4] Research and Development - Research and development expenses for 2024 amounted to RMB 137.21 million, primarily focused on post-marketing studies of the innovative HIV drug Aikening®[6] - The company is advancing its pipeline projects, with a first-in-class small nucleic acid candidate drug entering the IND enabling stage[11] - The company aims to obtain approval for the FB4001 (teriparatide injection generic) by 2025 and is actively promoting its progress[11] Product Development and Market Expansion - Aikening® has been included in the medical insurance "dual channel" and outpatient special directory in 29 provinces and municipalities[8] - The company is actively expanding Aikening®'s market presence in outpatient and inpatient settings, focusing on high-burden patients[7] - Aikening® has shown significant clinical benefits in treating HIV-infected patients, with a successful case study published in the international journal BMC Pregnancy and Childbirth[9]